{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007580","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.037442+00:00","generated_at":"2026-06-18T04:31:47.076672+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amylyx reports $22.2M full-year product revenue; net loss $198.4M","bullets":["Q4 net product revenue $21.9M; full-year 2022 net product revenue $22.2M from RELYVRIO/ALBRIOZA sales.","Net loss for 2022 was $198.4M ($3.39 per share) vs. $87.9M in 2021; cash & short-term investments $346.9M.","Phase 3 PHOENIX trial fully enrolled (664 participants); topline data expected mid-2024.","EU MAA regulatory review ongoing; company now expects CHMP opinion mid-2023 and decision Q3 2023 at earliest.","Karen Firestone appointed to Board of Directors effective March 16; raised $230.6M net in October 2022 public offering."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007580","json":"https://secwatch.observer/filing/0000950170-23-007580.json","markdown":"https://secwatch.observer/filing/0000950170-23-007580.md","text":"https://secwatch.observer/filing/0000950170-23-007580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023007580/0000950170-23-007580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023007580/amlx-20230313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:31:47.076672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a288fd18ad24a59fe1a827bb81eb7cf3fde46854","claim":"Amylyx Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $21.9 million, net income $42.7 million, or $0.65 per share.","evidence_excerpt":"For the three months ended December 31, 2022, net product revenue was $21.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023007580/0000950170-23-007580-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$21.9 million"},{"label":"Net income","value":"$42.7 million, or $0.65 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}